The FDA has approved Allecra Therapeutics' Exblifep, a combination antibiotic for complicated urinary tract infections (cUTIs ... caused by susceptible Gram-negative organisms.

Chinese researchers have swabbed the Chinese Tiangong Space Station and found a novel strain of bacterium called 'Niallia ...

noninterventional registry developed to collect real-world data on the use of daptomycin in the treatment of patients with Gram-positive infections. This subgroup analysis evaluated the safety and ...

Diagnosis of UTI is confirmed by a positive culture of an appropriate urine sample; much of the existing controversy is the result of the difficulty to obtain such a sample in young children.

The UTI Flexi Cap Fund Regular Plan Growth has an AUM of 24531.52 crores & has delivered CAGR of 21.08% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.67%.

The Scheme does not guarantee / indicate any returns. The UTI Dynamic Bond Fund Direct Plan Growth Option has an AUM of 465.14 crores & has delivered CAGR of 9.65% in the last 5 years. The fund ...

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...

Four tests that could allow people with urinary tract infections to receive the correct course of antibiotics more quickly are on course to be used by NHS hospitals, provided further research ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...